冷球蛋白血症性肾小球肾炎 中国就医指南

Cryoglobulinemic glomerulonephritis (CGN) is a rare, immune-mediated kidney disease characterized by the deposition of cryoglobulins—abnormal immunoglobulins that precipitate at low temperatures—in the glomeruli, triggering inflammation, endothelial injury, and progressive renal damage. It most commonly arises as a renal manifestation of cryoglobulinemic vasculitis, frequently associated with chronic hepatitis C virus (HCV) infection (Type II and III cryoglobulinemia), though it may also occur in autoimmune conditions (e.g., SLE, Sjögren’s syndrome), lymphoproliferative disorders (e.g., Waldenström macroglobulinemia), or idiopathically. Pathogenesis centers on immune complex formation: cryoglobulins—typically IgM-IgG (Type II) or polyclonal IgG/IgM (Type III)—circulate in the bloodstream and deposit in glomerular capillaries upon temperature-dependent precipitation or complement activation (especially via the lectin or alternative pathways), leading to mesangial hypercellularity, endocapillary proliferation, and often crescent formation. Histologically, light microscopy reveals membranoproliferative or proliferative patterns; immunofluorescence shows dominant IgM, IgG, and C3 deposits; electron microscopy demonstrates subendothelial and intramembranous electron-dense deposits. Epidemiologically, CGN is exceedingly rare, with an estimated incidence of <1 per million annually in general populations. It predominantly affects adults aged 50–70 years, with a slight female predominance. HCV remains the strongest modifiable risk factor—up to 90% of Type II/III cryoglobulinemia cases are HCV-associated—while other risks include HIV co-infection, chronic HBV, autoimmune dysregulation, B-cell malignancies, and prolonged exposure to environmental toxins or certain biologics. Untreated CGN carries high morbidity: rapid progression to nephrotic syndrome, acute kidney injury, or end-stage renal disease (ESRD) occurs in ~30–40% within 5 years. Patients frequently experience systemic symptoms—including purpura, arthralgia, peripheral neuropathy, and fatigue—alongside renal manifestations such as proteinuria, hematuria, hypertension, and declining eGFR. Quality of life is significantly impaired due to chronic fatigue, recurrent flares requiring hospitalization, dietary and fluid restrictions, anxiety about dialysis dependence, and psychosocial burden from visible vasculitic skin lesions and treatment-related side effects (e.g., corticosteroid-induced insomnia, mood changes, or rituximab-infusion reactions). Early diagnosis—via serum cryoglobulin testing (requiring strict pre-analytical handling at 37°C), renal biopsy, and HCV RNA screening—is critical. Prognosis improves markedly with timely, etiology-directed therapy, yet long-term monitoring for relapse, lymphoma development, and cardiovascular complications remains essential.

# 冷球蛋白血症性肾小球肾炎治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：轻中度蛋白尿（<3.5 g/d）、eGFR ≥60 mL/min/1.73m²、无急进性肾衰或严重系统性血管炎者。

• •基础治疗：糖皮质激素（泼尼松）+ 环磷酰胺/利妥昔单抗（一线免疫抑制）

• •支持治疗：ACEI/ARB降蛋白尿 + 抗凝（低分子肝素）+ 血浆白蛋白补充

• •检查检验费（首月）：冷球蛋白定量、补体C4/C3、ANCA、肾活检病理（含免疫荧光+电镜）、24h尿蛋白、eGFR监测等：3,200–4,800元

二、核心介入/强化治疗方案

适用人群：急进性肾炎（Scr 2周内↑≥50%）、新月体>50%、或利妥昔单抗无效者。

• •血浆置换（PE）联合免疫抑制：每周3次×2周，共6次（需中心静脉置管）

- 术前检查（凝血功能、感染四项、心超、中心静脉评估）：1,900–2,600元

三、特殊复杂/晚期方案

适用人群：终末期肾病（eGFR <15）、复发/耐药、合并HCV感染或淋巴瘤者。

• •HCV相关者加用直接抗病毒药物（索磷布韦/维帕他韦）：12,000–18,000元（12周）
• •终末期需维持性血液透析：450–650元/次（医保后自付约80–150元/次）

四、方案快速选择指南

• •预算有限/初发轻症：激素+环磷酰胺+支持治疗（首年总费用约3.5–5.5万元）
• •中高预算/中重度活动性病变：利妥昔单抗+血浆置换（首月投入约2.5–3.2万元）
• •晚期/并发症多：个体化多学科管理（肾内科+血液科+感染科），年均综合支出≥8万元